Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma

Table 3

Univariate and multivariate analyses for PFS.

Prognostic factors	Univariate analysis		Multivariate analysis
	HR (95% CI)	P	HR (95% CI)	P
Age ≥ 65 years	1.113 (0.671-1.844)	0.679
Hemoglobin < 100g/L	1.431 (0.900-2.274)	0.130
Serum albumin < 35g/L	1.437 (0.874-2.364)	0.153
Serum LDH ≥ 250U/L	2.820 (1.696-4.687)	< 0.001	1.673 (0.941-2.973)	0.080
Serum creatinine ≥ 177umol/L	2.113 (1.275-3.503)	0.004	1.005 (0.530-1.904)	0.989
Serum calcium ≥ 2.75mol/L	2.996 (1.489-6.032)	0.002	1.499 (0.685-3.278)	0.311
Serum β2-microglobulin ≥ 5.5mmol/L	2.541 (1.604-4.024)	< 0.001	1.758 (1.014-3.047)	0.044
1q21 gain	1.772 (1.121-2.800)	0.014	1.586 (0.994-2.529)	0.053
del (17p)	1.439 (0.758-2.731)	0.266
t (4;14)	1.079 (0.535-2.176)	0.831
t (11;14)	1.550 (0.901-2.668)	0.114
t (14;16)	1.638 (0.579-4.496)	0.338
LMR ≤ 4.2	2.387 (1.469-3.880)	< 0.001	1.831 (1.098-3.053)	0.021

Abbreviations: CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; PFS, progression-free survival